Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Status:
Completed
Trial end date:
2018-01-31
Target enrollment:
Participant gender:
Summary
Aprepitant is an oral neurokinin-1(NK-1) antagonist which is widely used for the prevention
of chemotherapy-induced nausea and vomiting(CINV), it is metabolized by CYP34A, however, up
to now it was still unknown the CINV control rate of aprepitant in Chinese non-small cell
lung cancer(NSCLC) patients, we hypothesis that CYP3A4 and NK-1 polymorphism would influence
aprepitant plasma concentration, which may lead to the individual difference of CINV control
rate.